Table 1.
A list of hedgehog signaling inhibitors in clinical trials (from http://clinicaltrials.gov)a
| Molecule | Other names | Phase | Tumor types | FDA approval | Company |
|---|---|---|---|---|---|
| GDC-0449 | Vismodegib/erivedge | I/II/III | BCCs and solid tumors | BCCs | Hoffmann-La Roche Ltd |
| IPI-926 | I/II | Solid tumors | Infinity Pharmaceuticals, Inc. | ||
| LDE225 | I/II | Leukemia and solid tumors | Novartis AG | ||
| LEQ506 | I | Solid tumors | Novartis AG | ||
| PF-04449913 | I/II | Leukemia and solid tumors | Pfizer, Inc. | ||
| TAK-441 | I | Solid tumors | Millennium Pharmaceuticals, Inc. | ||
| BMS833923 | XL-139 | I/II | SCLC and solid tumors | Bristol-Myers Squibb | |
| LY2940680 | I/II | SCLC/advanced cancer | Eli Lilly and Company |
Notes:
a
All small molecules target smoothened molecule. GDC-0449 has been approved by the FDA to treat locally advanced and metastatic BCCs. There are no ongoing clinical trials for LEQ506, TAK-441, and BMS833923.
Abbreviations: BCC, basal cell carcinoma; FDA, US Food and Drug Administration; SCLC, small cell lung cancer.